NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
BridgeBio Pharma, Inc. BBIO
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$502.1M
▲ 126.3% vs FY2024
EPS · FY25
$-3.78
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-146.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 502.1M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 146 cents on every revenue dollar this year.
Per share
USD -3.78
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-104.2%
Net margin-146.0%
Return on assets-79.0%
Returned to shareholders
USD 48.3M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 48.3M
Share of profit-6.6%
Consecutive raises—
USD 48.3M in buybacks went back to shareholders in a year without profit.
Growth
+127.4% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+86.3%
+127.4%
Returned to shareholders
−8.4%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.19B
Shares outstanding, FY2025
Change, 5 years+58.5%
Change, 10 years—
The share count grew 59% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 936.0M
total assets, end of FY2025
Total assetsUSD 936.0M
EquityUSD -2.1B
CashUSD 570.1M
Gross debtUSD 2.0B
Net debtUSD 1.4B
Current ratio2.77×
Net debt stands at -69% of equity.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.5
0.2
0.0
0.1
0.1
0.0
0.0
·
·
Operating income $B
−0.5
−0.6
−0.6
−0.5
−0.6
−0.5
−0.3
−0.2
−0.0
EBITDA $B
−0.5
−0.6
−0.6
−0.5
−0.6
−0.5
−0.3
·
·
Income tax $B
0.0
0.0
0.0
0.0
·
·
·
·
·
Net income $B
−0.7
−0.5
−0.7
−0.5
−0.6
−0.5
−0.3
−0.2
−0.0
EPS, diluted $
−3.78
−2.88
−3.95
−3.26
−3.90
−3.80
−2.48
−2.12
−1.00
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
−0
·
−3
ROE %
·
·
·
·
·
−216.8
−79.8
−84.6
−51.1
Shares out B
0.19
0.19
0.18
0.15
0.15
0.12
0.12
0.09
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
25 of 25
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed